Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGIR | P43119 | 4/20 | 0.43 |
| ▸ | FAAH | O00519 | 5/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.36 |
| ▸ | RXRA | P19793 | 2/20 | 0.36 |
| ▸ | RXRB | P28702 | 2/20 | 0.36 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 3/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CASP1 | P29466 | 1/20 | 0.35 |
| ▸ | CASP7 | P55210 | 1/20 | 0.35 |
| ▸ | PTGER2 | P43116 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL363291 | 0.88 | PTGIR (0.46) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL361862 | 0.88 | PTGIR (0.46) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL362965 | 0.88 | PTGIR (0.46) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL362663 | 0.87 | PTGIR (0.45) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL361684 | 0.85 | PTGIR (0.43) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL360659 | 0.85 | PTGIR (0.43) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL363081 | 0.84 | PTGIR (0.42) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL361142 | 0.84 | PTGIR (0.44) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL362273 | 0.84 | PTGIR (0.42) | PTGIRFAAHKDM4EHSD17B10RXRA | |
| SCHEMBL362482 | 0.81 | ALDH1A1 (0.37) | PTGIRRXRARXRBALDH1A1PTGER2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| EP-2593452-B1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2017-01-18 | — | — | EP | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-9132127-B2 | Substituted pyrido[2,3-B]pyrazines as IP receptor agonists | NOVARTIS AG (CH) | 2015-09-15 | — | — | US | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2014-08-28 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| US-8754085-B2 | Pyrido[2,3-b]pyrazine compounds useful as IP receptor agonist | NOVARTIS AG (CH) | 2014-06-17 | — | — | US | disclosed |
| EP-2593452-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | Novartis AG (CH) | 2013-05-22 | — | — | EP | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A9 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-11-01 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
| WO-2012007539-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | NOVARTIS AG (CH) | 2012-01-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140243346-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | PTGIR 1/4885FAAH 1419/4885KDM4E 3335/4885 |
| US-20130102611-A1 | IP RECEPTOR AGONIST HETEROCYCLIC COMPOUNDS | PTGIR, ACVR1, PTGFR | PTGIR 1/4885FAAH 1419/4885KDM4E 3335/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.